The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
MERUS N V | COM | N5749R100 | 22,528 | 1,600,000 | SH | SOLE | 1,2,3 | 1,600,000 | 0 | 0 | |
OBSEVA SA | COM | H5861P103 | 5,997 | 1,570,000 | SH | SOLE | 1,2,3 | 1,570,000 | 0 | 0 | |
PHATHOM PHARMACEUTICALS INC | COM | 71722W107 | 64,393 | 2,067,861 | SH | SOLE | 1,2,3 | 2,067,861 | 0 | 0 | |
SYNTHORX INC | COM | 87167A103 | 70,252 | 1,005,184 | SH | SOLE | 1,2,3 | 1,005,184 | 0 | 0 |